All Stories

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Article • Leukemia, February 2020, Springer Science + Business Media

    MD PhD ELISA E LUÑO

  2. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

    Article • Leukemia & Lymphoma, December 2018, Taylor & Francis

    Professor Josep-Maria Ribera, MD PhD ELISA E LUÑO

  3. rs2431697, a Polymorphism of Mir-146a, Is a Precozing Marker of Progression to Secondary Myelofibrosis: New Epigenetic Regulation of Jak/Stat3 Signaling

    Article • Blood, November 2018, American Society of Hematology

    MD PhD ELISA E LUÑO

  4. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

    Article • Genes Chromosomes and Cancer, September 2018, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  5. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

    Article • Blood Advances, August 2018, American Society of Hematology

    MD PhD ELISA E LUÑO

  6. Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries

    Article • British Journal of Haematology, April 2018, Wiley

    MD PhD ELISA E LUÑO

  7. Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

    Article • Leukemia Research, April 2018, Elsevier

    MD PhD ELISA E LUÑO

  8. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

    Article • Leukemia, March 2018, Springer Science + Business Media

    MD PhD ELISA E LUÑO

  9. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia

    Article • Molecular Cancer Therapeutics, February 2018, American Association for Cancer Research (AACR)

    MD PhD ELISA E LUÑO

  10. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Article • Leukemia Research, December 2017, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  11. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Article • Cancer Letters, November 2017, Elsevier

    MD PhD ELISA E LUÑO

  12. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia

    Article • Leukemia & Lymphoma, July 2017, Taylor & Francis

    MD PhD ELISA E LUÑO

  13. PATIENT CONDITION MAY BE MORE IMPORTANT FOR SURVIVAL THAN MUTATIONAL ANALYSIS IN MDS

    Article • American Journal of Hematology, July 2017, Wiley

    Dr Fernando Ramos, MD PhD ELISA E LUÑO

  14. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance

    Article • American Journal of Hematology, June 2017, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  15. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)

    Article • American Journal of Hematology, May 2017, Wiley

    MD PhD ELISA E LUÑO , Dr Fernando Ramos, Xavier Calvo

  16. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

    Article • Oncotarget, April 2017, Impact Journals, LLC

    MD PhD ELISA E LUÑO

  17. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    Article • British Journal of Haematology, April 2017, Wiley

    MD PhD ELISA E LUÑO

  18. The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells

    Article • Leukemia Research, April 2017, Elsevier

    MD PhD ELISA E LUÑO

  19. Health outcomes research study on patients with type 1 Gaucher disease under substrate reduction therapy (SRT)

    Article • Molecular Genetics and Metabolism, January 2017, Elsevier

    MD PhD ELISA E LUÑO

  20. Excess mortality in the myelodysplastic syndromes

    Article • American Journal of Hematology, December 2016, Wiley

    Dr Fernando Ramos, MD PhD ELISA E LUÑO

  21. Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes

    Article • Blood, December 2016, American Society of Hematology

    MD PhD ELISA E LUÑO

  22. Considering Bone Marrow Blasts from Nonerythroid Cells Improves the Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts

    Article • Blood, December 2016, American Society of Hematology

    MD PhD ELISA E LUÑO

  23. Considering Bone Marrow Blasts from Nonerythroid Cellularity Improves the Prognostic Evaluation of MDS in the Context of IPSS-R and Permits a Better Risk Assessment of MDS Patients Classified into the Intermediate Risk Category

    Article • Blood, December 2016, American Society of Hematology

    MD PhD ELISA E LUÑO

  24. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Article • Oncotarget, November 2016, Impact Journals, LLC

    MD PhD ELISA E LUÑO

  25. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project

    Article • Blood Cells Molecules and Diseases, October 2016, Elsevier

    MD PhD ELISA E LUÑO

  26. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes

    Article • Journal of Clinical Oncology, September 2016, American Society of Clinical Oncology (ASCO)

    MD PhD ELISA E LUÑO

  27. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

    Article • Modern Pathology, August 2016, Nature

    MD PhD ELISA E LUÑO

  28. Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference

    Article • Haematologica, April 2016, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO

  29. Impact of anaemia on health-related quality of life and cardiac remodelling in patients with lower risk myelodysplastic syndromes. Results of GlobQoL study

    Article • European Journal of Cancer Care, January 2016, Wiley

    Dr Fernando Ramos, MD PhD ELISA E LUÑO

  30. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status

    Article • Blood Cells Molecules and Diseases, January 2016, Elsevier

    MD PhD ELISA E LUÑO

  31. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes

    Article • Genes Chromosomes and Cancer, December 2015, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  32. Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

    Article • Blood, December 2015, American Society of Hematology

    MD PhD ELISA E LUÑO

  33. Myelodysplastic Syndromes (MDS) with Erythroid Hyperplasia: Enumerating Blasts from Non-Erythroid Cell Compartment Improves the Risk Stratification of MDS with Excess of Blasts

    Article • Blood, December 2015, American Society of Hematology

    MD PhD ELISA E LUÑO

  34. A Low Frequency of Losses in 11q Chromosome Is Associated with Better Outcome and Lower Rate of Genomic Mutations in Patients with Chronic Lymphocytic Leukemia

    Article • PLoS ONE, December 2015, PLOS

    MD PhD ELISA E LUÑO

  35. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia

    Article • European Journal Of Haematology, October 2015, Wiley

    MD PhD ELISA E LUÑO

  36. Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?

    Article • PLoS ONE, June 2015, PLOS

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  37. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study

    Article • The Lancet Haematology, June 2015, Elsevier

    MD PhD ELISA E LUÑO

  38. Fluorescencein situhybridization ofTP53for the detection of chromosome 17 abnormalities in myelodysplastic syndromes

    Article • Leukemia & Lymphoma, May 2015, Taylor & Francis

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  39. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry

    Article • Leukemia, May 2015, Nature

    MD PhD ELISA E LUÑO

  40. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

    Article • British Journal of Haematology, April 2015, Wiley

    MD PhD ELISA E LUÑO

  41. 261 ERYTHROLEUKEMIA APPEARS TO BE A CONTINUUM OF MDS WITH ERYTHROID HYPERPLASIA AND SHARES OUTCOME AND CYTOGENETIC FEATURES WITH RAEB-1 WITH ≥50% ERYTHROPOIESIS

    Article • Leukemia Research, April 2015, Elsevier

    MD PhD ELISA E LUÑO

  42. 260 CONSIDERING PERCENTAGE OF BLASTS ON THE BASIS OF NON-ERYTHROID COMPARTMENT MIGHT IMPROVE THE CLASSIFICATION AND PROGNOSTICATION OF MDS WITH EXCESS OF BLAST CELLS

    Article • Leukemia Research, April 2015, Elsevier

    MD PhD ELISA E LUÑO

  43. 213 AZACITIDINE (AZA) IN HIGHER RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES (ABN 7): RESULTS OF A RETROSPECTIVE STUDY FROM THE GFM AND GESMD REGISTRIES

    Article • Leukemia Research, April 2015, Elsevier

    MD PhD ELISA E LUÑO

  44. 211 SPANISH REGISTRY OF ERYTHROPOIETIC STIMULATING AGENTS STUDY: THE LARGEST RETROSPECTIVE STUDY OF ESAS FOR THE TREATMENT OF ANEMIA IN LOWER RISK MDS PATIENTS

    Article • Leukemia Research, April 2015, Elsevier

    MD PhD ELISA E LUÑO

  45. Correlation of myelodysplastic syndromes with i(17)(q10) andTP53andSETBP1mutations

    Article • British Journal of Haematology, February 2015, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  46. Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3

    Article • Hematology, February 2015, Taylor & Francis

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  47. Epidemiological assessment of Spanish patients with type 1 Gaucher disease using the therapeutic goals MAP Tool®

    Article • Molecular Genetics and Metabolism, February 2015, Elsevier

    MD PhD ELISA E LUÑO

  48. Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)

    Article • Blood, December 2014, American Society of Hematology

    MD PhD ELISA E LUÑO

  49. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome

    Article • Genes Chromosomes and Cancer, June 2014, Wiley

    MD PhD ELISA E LUÑO

  50. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Article • Leukemia Research, May 2014, Elsevier

    MD PhD ELISA E LUÑO

  51. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    Article • British Journal of Haematology, April 2014, Wiley

    MD PhD ELISA E LUÑO

  52. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Article • Leukemia Research, March 2014, Elsevier

    MD PhD ELISA E LUÑO

  53. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

    Article • Haematologica, January 2014, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO

  54. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis

    Article • Leukemia, January 2014, Nature

    MD PhD ELISA E LUÑO

  55. Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry

    Article • Clinical Cancer Research, December 2013, American Association for Cancer Research (AACR)

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  56. Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

    Article • Genes Chromosomes and Cancer, October 2013, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  57. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

    Article • Leukemia & Lymphoma, September 2013, Taylor & Francis

    MD PhD ELISA E LUÑO

  58. Survey on the Culture of Patient Safety Among Spanish Health Care Residents

    Article • American Journal of Medical Quality, September 2013, SAGE Publications

    MD PhD ELISA E LUÑO

  59. Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion

    Article • British Journal of Haematology, July 2013, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  60. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome

    Article • Leukemia Research, July 2013, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  61. Monosomal karyotype in MDS: explaining the poor prognosis?

    Article • Leukemia, June 2013, Nature

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  62. Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype

    Article • Genes Chromosomes and Cancer, May 2013, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  63. P-068 Trisomy 8 in de novo MDS, constitutional or not constitutional?

    Article • Leukemia Research, May 2013, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  64. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis

    Article • Leukemia, April 2013, Nature

    MD PhD ELISA E LUÑO

  65. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does −7/7q− detection by FISH have prognostic value?

    Article • Leukemia Research, April 2013, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  66. Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome

    Article • Journal of Clinical Oncology, March 2013, American Society of Clinical Oncology (ASCO)

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  67. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia

    Article • Blood, January 2013, American Society of Hematology

    MD PhD ELISA E LUÑO

  68. Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)

    Article • Blood, November 2012, American Society of Hematology

    MD PhD ELISA E LUÑO

  69. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes

    Article • Haematologica, October 2012, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO

  70. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

    Article • British Journal of Haematology, September 2012, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  71. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

    Article • Haematologica, April 2012, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO

  72. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

    Article • Journal of Clinical Oncology, March 2012, American Society of Clinical Oncology (ASCO)

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  73. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Article • Leukemia Research, March 2012, Elsevier

    MD PhD ELISA E LUÑO

  74. Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML)

    Article • Leukemia Research, March 2012, Elsevier

    MD PhD ELISA E LUÑO

  75. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

    Article • Leukemia Research, September 2011, Elsevier

    MD PhD ELISA E LUÑO

  76. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Article • Cancer, June 2011, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  77. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Article • Cancer, June 2011, Wiley

    MD PhD ELISA E LUÑO

  78. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome

    Article • Leukemia Research, June 2011, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  79. 122 SNP-A karyotyping in MDS and MDS/MPN cases with normal karyotype

    Article • Leukemia Research, May 2011, Elsevier

    MD PhD ELISA E LUÑO

  80. 108 SNP-A karyotyping in primary myelodysplastic syndromes with unsuccessful routine cytogenetic testing

    Article • Leukemia Research, May 2011, Elsevier

    MD PhD ELISA E LUÑO

  81. 298 Chromosome 7 abnormalities in MDS

    Article • Leukemia Research, May 2011, Elsevier

    MD PhD ELISA E LUÑO

  82. 297 Prognostic impact of severe thrombocytopenia in low risk myelodysplastic syndrome

    Article • Leukemia Research, May 2011, Elsevier

    MD PhD ELISA E LUÑO

  83. 64 A retrospective time-dependent comparative analysis of the impact of lenalidomide on outcomes in lower risk MDS with chromosome 5q deletion

    Article • Leukemia Research, May 2011, Elsevier

    MD PhD ELISA E LUÑO

  84. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

    Article • Current Medical Research and Opinion, March 2011, Informa Healthcare

    MD PhD ELISA E LUÑO

  85. Regulation of the expression of death receptors and their ligands by melatonin in haematological cancer cell lines and in leukaemia cells from patients

    Article • Journal of Pineal Research, February 2011, Wiley

    MD PhD ELISA E LUÑO

  86. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage

    Article • Blood Cells Molecules and Diseases, January 2011, Elsevier

    MD PhD ELISA E LUÑO

  87. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Article • Haematologica, November 2010, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  88. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

    Article • Leukemia, September 2010, Nature

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  89. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group

    Article • Blood, May 2010, American Society of Hematology

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  90. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma

    Article • Genes Chromosomes and Cancer, January 2010, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  91. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Article • Haematologica, November 2009, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO

  92. P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia

    Article • Leukemia Research, May 2009, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  93. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome

    Article • Leukemia Research, May 2009, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  94. P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

    Article • Leukemia Research, May 2009, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  95. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status

    Article • International Journal of Hematology, September 2008, Springer Science + Business Media

    MD PhD ELISA E LUÑO

  96. New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY)

    Article • Leukemia Research, May 2008, Elsevier

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  97. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

    Article • Haematologica, January 2008, Ferrata Storti Foundation (Haematologica)

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  98. Additional Chromosome Abnormalities Have No Prognostic Value in Acute Promyelocytic Leukemia Patients Treated with Simultaneous ATRA and Anthracycline-Based Chemotherapy: An Update of the APL96 and APL99 Pethema Protocols.

    Article • Blood, November 2004, American Society of Hematology

    MD PhD ELISA E LUÑO

  99. Translocation (3;10)(q26;q22)

    Article • Cancer Genetics and Cytogenetics, August 2000, Elsevier

    MD PhD ELISA E LUÑO

  100. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

    Article • British Journal of Haematology, February 2000, Wiley

    MD PhD ELISA E LUÑO , FRANCESC SOLE

  101. Trisomy 10 in acute myeloid leukemia: Report of a new case

    Article • Cancer Genetics and Cytogenetics, January 1998, Elsevier

    MD PhD ELISA E LUÑO

  102. 124 Cytogenetic study of 36 patients with secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia(AML)

    Article • Leukemia Research, April 1997, Elsevier

    MD PhD ELISA E LUÑO

  103. Chronic myelogenous leukemia and glomerulonephritis: report of a new case

    Article • The American Journal of Medicine, December 1986, Elsevier

    MD PhD ELISA E LUÑO